SCHEMBL4908835

SCHEMBL4908835

COc1cncc(-c2ncnc(Cl)c2C#N)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 4/20 0.44
CYP11B2 P19099 4/20 0.44
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
CYP17A1 P05093 2/20 0.39
CYP3A4 P08684 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP1A1 P04798 2/20 0.38
CYP1B1 Q16678 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KDM4E B2RXH2 4/20 0.37
NPSR1 Q6W5P4 2/20 0.37
RXFP1 Q9HBX9 2/20 0.37
GLA P06280 2/20 0.37
LRRK2 Q5S007 1/20 0.37
MAPT P10636 1/20 0.37
ADORA2A P29274 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898180 0.84 CYP11B1 (0.44) CYP11B1CYP11B2CYP17A1CYP3A4CYP1A2
SCHEMBL4903707 0.80 ALDH1A1 (0.49) CYP11B1CYP11B2ALDH1A1HPGDCYP17A1
SCHEMBL4911968 0.79 ADORA1 (0.53) CYP11B1CYP11B2ALDH1A1HPGDKMT2A
SCHEMBL4900833 0.77 KMT2A (0.56) CYP11B1CYP11B2ALDH1A1HPGDCYP17A1
SCHEMBL13946838 0.74 CYP11B1 (0.42) CYP11B1CYP11B2ALDH1A1HPGDCYP3A4
SCHEMBL4908545 0.73 BRAF (0.49) CYP11B1CYP11B2ALDH1A1HPGDKMT2A
SCHEMBL4900936 0.69 CYP11B1 (0.43) CYP11B1CYP11B2CYP17A1CYP3A4CYP1A2
SCHEMBL30980813 0.69 CYP11B1 (0.45) CYP11B1CYP11B2ALDH1A1HPGDCYP17A1
SCHEMBL4899129 0.68 ADORA1 (0.53) CYP11B1CYP11B2CYP3A4CYP1A2CYP2C9
SCHEMBL4909592 0.68 KMO (0.53) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF CYP11B1 609/4885CYP11B2 1096/4885ALDH1A1 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.